The development of new drugs, including antineoplastic drugs, is a complex process of systematic analysis of the properties of the molecules developed. Despite the progress of basic research and the development of new treatment strategies, many types of cancer remain incurable. One of the features of cancer cells is the altered activity of different proteins, allowing cells, for example, unlimited proliferation or increased service life. Kinases are such a group of proteins that are responsible for phosphorylation of other proteins, contributing to their activation. This phenomenon is observed in a number of types of cancer. Many of the first generations of chemotherapists are compounds with, in addition to the desired properties, a number of important defects resulting from the lack of selectivity of therapy and side effects. The aim of the project will be to develop small molecular inhibitors with a confirmed selective mechanism of action. The development of studies allowed the identification of protein molecular targets, markers of efficacy and toxicity, and competent selection of patients. Based on this knowledge, new active molecules will be developed, enabling a targeted therapeutic approach. These molecules, in addition to the greater efficacy provided by personalised pharmacotherapy, will have a high safety of use thanks to the specificity of the action. The molecular targets selected in the project offer a good chance of getting a first-in-class drug. The developed pivotal compounds will be fully characterised by pharmacodynamic and pharmacokinetic characteristics and a GLP standard of toxicology and safety pharmacology will be performed for the selected clinical candidate. The project also planned to synthesis the active substance in the required amount in the GMP standard and to carry out 0 phase/early phase I clinical trials.